Tango Therapeutics
Doug Barry joined Tango from Alexion Pharmaceuticals, acquired by AstraZeneca PLC in July 2021, where he served as Vice President of Corporate Law. During his three years at Alexion, Doug was responsible for public reporting, corporate governance, financing transactions, and litigation. Prior to Alexion, Doug was the Associate General Counsel at Alere Inc., which was acquired by Abbott Laboratories. He has been practicing law for over 20 years.
Doug has a Bachelor of Arts degree in political science from Hobart College, a master’s degree from University of Virginia in international relations, and a juris doctor from Northwestern University School of Law.
This person is not in any offices
Tango Therapeutics
3 followers
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients.